| Year |
Citation |
Score |
| 2022 |
Wang S, Luke CJ, Pak SC, Shi V, Chen L, Moore J, Andress AP, Jayachandran K, Zhang J, Huang Y, Platik M, Apicelli AA, Schwarz JK, Grigsby PW, Silverman GA, ... Markovina S, et al. SERPINB3 (SCCA1) inhibits cathepsin L and lysoptosis, protecting cervical cancer cells from chemoradiation. Communications Biology. 5: 46. PMID 35022555 DOI: 10.1038/s42003-021-02893-6 |
0.305 |
|
| 2020 |
Contreras J, Srivastava A, Chundury A, Schwarz JK, Markovina S, Thaker PH, Massad LS, Mutch DG, Powell MA, Grigsby PW, Lin AJ. Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 32527770 DOI: 10.1136/Ijgc-2020-001412 |
0.348 |
|
| 2020 |
Wang S, Luke C, Shi V, Grigsby P, Silverman G, Markovina S. Abstract 2426: SERPINB3 promotes radiation resistance in cervical cancer by inhibiting lysosome-mediated cell death Cancer Research. 80: 2426-2426. DOI: 10.1158/1538-7445.Am2020-2426 |
0.424 |
|
| 2019 |
Cosper PF, McNair C, González I, Wong N, Knudsen KE, Chen JJ, Markovina S, Schwarz JK, Grigsby PW, Wang X. Decreased Local Immune Response and Retained HPV Gene Expression during Chemoradiotherapy are Associated with Treatment Resistance and Death from Cervical Cancer. International Journal of Cancer. PMID 31732968 DOI: 10.1002/Ijc.32793 |
0.341 |
|
| 2019 |
Wisdom AJ, Hong CS, Lin AJ, Xiang Y, Cooper DE, Zhang J, Xu ES, Kuo HC, Mowery YM, Carpenter DJ, Kadakia KT, Himes JE, Luo L, Ma Y, Williams N, ... ... Markovina S, et al. Neutrophils promote tumor resistance to radiation therapy. Proceedings of the National Academy of Sciences of the United States of America. PMID 31462499 DOI: 10.1073/Pnas.1901562116 |
0.411 |
|
| 2019 |
Lin AJ, Samson P, Zoberi J, Garcia-Ramirez J, Williamson JF, Markovina S, Schwarz J, Grigsby PW. Concurrent chemoradiation for cervical cancer: Comparison of LDR and HDR brachytherapy. Brachytherapy. PMID 30971370 DOI: 10.1016/J.Brachy.2018.11.008 |
0.316 |
|
| 2019 |
Lin AJ, Ma S, Markovina S, Schwarz J, Mutch DG, Powell MA, Grigsby PW. Clinical outcomes after isolated pelvic failure in cervical cancer patients treated with definitive radiation. Gynecologic Oncology. PMID 30905434 DOI: 10.1016/J.Ygyno.2019.03.104 |
0.349 |
|
| 2019 |
Hassanzadeh C, Srivastava A, Markovina S, Schwarz J, Grigsby P. Prognostic Significance of pl6 in Patients with Cervical Cancer Receiving Definitive Chemoradiation International Journal of Radiation Oncology*Biology*Physics. 103: E33. DOI: 10.1016/S0360-3016(19)30480-8 |
0.341 |
|
| 2019 |
Huepenbecker S, Lange S, Chin R, Wan L, Markovina S, Fuh K, Hagemann A, Kuroki L, Thaker P, Powell M, Mutch D, McCourt C. Fistula formation in cervical cancer patients treated with bevacizumab: Pharmacovigilance after GOG 240 Gynecologic Oncology. 154: 144-145. DOI: 10.1016/J.Ygyno.2019.04.341 |
0.332 |
|
| 2018 |
Lin AJ, Hassanzadeh C, Markovina S, Schwarz J, Grigsby P. Brachytherapy and survival in small cell cancer of the cervix and uterus. Brachytherapy. PMID 30563743 DOI: 10.1016/J.Brachy.2018.11.006 |
0.33 |
|
| 2018 |
Lin AJ, Samson P, DeWees T, Henke L, Baranski T, Schwarz J, Pfeifer J, Grigsby P, Markovina S. A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer. Cancer Medicine. PMID 30552739 DOI: 10.1002/Cam4.1857 |
0.305 |
|
| 2018 |
Lin AJ, Kidd E, Dehdashti F, Siegel BA, Mutic S, Thaker PH, Massad LS, Powell MA, Mutch DG, Markovina S, Schwarz J, Grigsby PW. IMRT and image-guided adapted brachytherapy for cervix cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 30445171 DOI: 10.1016/J.Ijrobp.2018.11.012 |
0.3 |
|
| 2018 |
Patel RB, Baniel CC, Sriramaneni RN, Bradley K, Markovina S, Morris ZS. Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. Brachytherapy. PMID 30078541 DOI: 10.1016/J.Brachy.2018.07.004 |
0.313 |
|
| 2018 |
Markovina S, Meeks MW, Badiyan S, Vetter J, Gay HA, Paradis A, Michalski J, Sandhu G. Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis. Advances in Radiation Oncology. 3: 190-196. PMID 29904744 DOI: 10.1016/J.Adro.2017.12.001 |
0.326 |
|
| 2018 |
Chapman W, Roxburgh C, Makhdoom B, Roy A, Youssef F, Brady P, Olsen J, Kim H, Pedersen K, Mutch M, Hunt S, Markovina S, Hajj C, Cercek A, Weiser M, et al. Rectal Cancer Downstaging is Significantly Improved with Different Regimens of Total Neoadjuvant Therapy International Journal of Radiation Oncology*Biology*Physics. 102: S65-S66. DOI: 10.1016/J.Ijrobp.2018.06.181 |
0.335 |
|
| 2017 |
Huynh M, Pak C, Markovina S, Callander NS, Chng KS, Wuerzberger-Davis SM, Bakshi DD, Kink JA, Hematti P, Hope C, Asimakopoulos F, Rui L, Miyamoto S. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma. The Journal of Biological Chemistry. PMID 29279332 DOI: 10.1074/Jbc.Ra117.000667 |
0.732 |
|
| 2017 |
Markovina S, Wang S, Henke LE, Luke CJ, Pak SC, DeWees T, Pfeifer JD, Schwarz JK, Liu W, Chen S, Mutch D, Wang X, Powell MA, Siegel BA, Dehdashti F, et al. Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. British Journal of Cancer. PMID 29112685 DOI: 10.1038/Bjc.2017.390 |
0.37 |
|
| 2017 |
Markovina S, Youssef F, Roy A, Aggarwal S, Khwaja S, DeWees T, Tan B, Hunt S, Myerson RJ, Chang DT, Parikh PJ, Olsen JR. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis. International Journal of Radiation Oncology, Biology, Physics. 99: 417-426. PMID 28871992 DOI: 10.1016/J.Ijrobp.2017.05.048 |
0.377 |
|
| 2017 |
Rao YJ, Chin RI, Hui C, Mutch DG, Powell MA, Schwarz JK, Grigsby PW, Markovina S. Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database. Gynecologic Oncology. PMID 28662775 DOI: 10.1016/J.Ygyno.2017.06.022 |
0.381 |
|
| 2017 |
Markovina S, Wang S, Cosper P, Luke C, Pak S, Liu W, Chen S, Schwarz J, Wang X, Silverman G, Grigsby P. Squamous Cell Carcinoma Antigen Mediates Radiation Resistance in Cervical Cancer International Journal of Radiation Oncology*Biology*Physics. 99: S146-S147. DOI: 10.1016/J.Ijrobp.2017.06.339 |
0.38 |
|
| 2017 |
Weiner A, Chen I, Curcuru A, Henke L, Green O, Markovina S, Gay H, Robinson C, Roach M, Olsen J, Kashani R, Parikh P. (P031) Early Clinical Experience in High Dose MRI Guided Adaptive Radiation Therapy for Inoperable Pancreatic Cancer International Journal of Radiation Oncology*Biology*Physics. 98: E23. DOI: 10.1016/J.Ijrobp.2017.02.126 |
0.316 |
|
| 2016 |
Roy A, Olsen JR, Myerson RJ, Markovina S, DeWees TA, Parikh PJ. Short-Term Endpoints for Neoadjuvant Rectal Cancer Therapy: Pathologic Complete Response or Neoadjuvant Rectal Cancer Score? International Journal of Radiation Oncology, Biology, Physics. 96: E201. PMID 27674050 DOI: 10.1016/J.Ijrobp.2016.06.1096 |
0.315 |
|
| 2016 |
Khwaja SS, Roy A, Markovina S, Dewees TA, Hunt S, Tan B, Myerson RJ, Olsen JR, Parikh PJ. Quality of Life Outcomes From a Phase 2 Trial of Short-Course Radiation Therapy Followed by FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 27209506 DOI: 10.1016/J.Ijrobp.2016.03.020 |
0.317 |
|
| 2015 |
Markovina S, Duan F, Snyder BS, Siegel BA, Machtay M, Bradley JD. Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235. International Journal of Radiation Oncology, Biology, Physics. 93: 597-605. PMID 26461002 DOI: 10.1016/J.Ijrobp.2015.04.026 |
0.311 |
|
| 2015 |
Youssef F, Markovina S, Khwaja S, DeWees T, Hunt S, Tan B, Myerson R, Parikh P, Olsen J. Matched Pair Analysis of Sequential Short Course Radiation Therapy and FOLFOX Chemotherapy as Preoperative Therapy for Rectal Cancer: Improved DFS Compared to Institutional Controls Favors Near-Total Neoadjuvant Therapy International Journal of Radiation Oncology*Biology*Physics. 93: S125. DOI: 10.1016/J.Ijrobp.2015.07.298 |
0.334 |
|
| 2014 |
Markovina S, Weschenfelder DC, Gay H, McCandless A, Carey B, DeWees T, Knutson N, Michalski J. Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer. Practical Radiation Oncology. 4: 430-6. PMID 25407866 DOI: 10.1016/J.Prro.2014.02.004 |
0.314 |
|
| 2014 |
Badiyan SN, Markovina S, Simpson JR, Robinson CG, DeWees T, Tran DD, Linette G, Jalalizadeh R, Dacey R, Rich KM, Chicoine MR, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, et al. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. International Journal of Radiation Oncology, Biology, Physics. 90: 877-85. PMID 25257812 DOI: 10.1016/J.Ijrobp.2014.07.014 |
0.314 |
|
| 2014 |
Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemotherapy and Pharmacology. 74: 875-82. PMID 25168296 DOI: 10.1007/S00280-014-2550-5 |
0.583 |
|
| 2014 |
Markovina S, Henke L, Pak S, DeWees T, Silverman G, Pfeifer J, Grigsby P. On-Treatment Serum Squamous Cell Carcinoma Antigen (SCCA) Predicts Response to Therapy on Posttherapy FDG-PET and Recurrence in Women Treated With Chemoradiation for Squamous Cancer of the Cervix International Journal of Radiation Oncology*Biology*Physics. 90: S93. DOI: 10.1016/J.Ijrobp.2014.05.492 |
0.323 |
|
| 2014 |
Khwaja S, Markovina S, Hunt S, Tan B, Myerson R, Parkih P, Olsen J. Patient-Reported QOL Outcomes From a Prospective Phase 2 Trial of Short Course Radiation Therapy Followed by FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S712-S713. DOI: 10.1016/J.Ijrobp.2014.05.2084 |
0.367 |
|
| 2014 |
Weiner A, Markovina S, Khwaja S, DeWees T, Hunt S, Myerson R, Parikh P, Olsen J. Neoadjuvant Rectal Cancer (NAR) Score Applied to Phase 2 Trial of Short Course Radiation (RT) and FOLFOX as Preoperative Therapy for Rectal Cancer Supports a Total Neoadjuvant Approach International Journal of Radiation Oncology*Biology*Physics. 90: S389. DOI: 10.1016/J.Ijrobp.2014.05.1247 |
0.343 |
|
| 2013 |
Markovina S, McCandless A, Badiyan S, Gay H, Mullen D, Eschen L, DeWees T, Michalski J. Risk of Biochemical Failure in Patients With High-Risk Prostate Cancer Treated Definitively or Postoperatively With Intensity Modulated Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 87: S390. DOI: 10.1016/J.Ijrobp.2013.06.1022 |
0.314 |
|
| 2012 |
Humbert AT, Cook R, McFarland T, Go R, Markovina S, Miyamoto S, Williams EC, Asimakopoulos F, Kolesar J, Thompson MA, Kim K, Callander N. Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma Blood. 120: 5041-5041. DOI: 10.1182/Blood.V120.21.5041.5041 |
0.562 |
|
| 2010 |
Markovina S, Callander NS, O'Connor SL, Xu G, Shi Y, Leith CP, Kim K, Trivedi P, Kim J, Hematti P, Miyamoto S. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Molecular Cancer. 9: 176. PMID 20604947 DOI: 10.1186/1476-4598-9-176 |
0.716 |
|
| 2009 |
Callander NS, Markovina S, Juckett MB, Wagner E, Kolesar J, Longo W, Williams EC, Kim K, Werndli J, Miyamoto S. The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317). Blood. 114: 3885-3885. DOI: 10.1182/Blood.V114.22.3885.3885 |
0.589 |
|
| 2008 |
Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Molecular Cancer Research : McR. 6: 1356-64. PMID 18708367 DOI: 10.1158/1541-7786.Mcr-08-0108 |
0.72 |
|
| 2008 |
Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Molecular Cancer. 7: 40. PMID 18489772 DOI: 10.1186/1476-4598-7-40 |
0.637 |
|
| 2008 |
Mishra MV, Bisht KS, Sun L, Muldoon-Jacobs K, Awwad R, Kaushal A, Nguyen P, Huang L, Pennington JD, Markovina S, Bradbury CM, Gius D. DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells. Molecular Cancer Research : McR. 6: 243-9. PMID 18314485 DOI: 10.1158/1541-7786.Mcr-07-0373 |
0.38 |
|
| 2006 |
Callander NS, Miyamoto S, Kahl B, Markovina S, Raschko M, Werndl J, Leith C, McCoy A. Phase II Trial of Bortezomib Combined with Weekly Doxorubicin and Oral Dexamethasone for Relapsed or Refractory Multiple Myeloma (MM): Effect of NF-κB Activation on Response. Blood. 108: 3545-3545. DOI: 10.1182/Blood.V108.11.3545.3545 |
0.648 |
|
| 2005 |
O'Connor S, Markovina S, Miyamoto S. Evidence for a phosphorylation-independent role for Ser 32 and 36 in proteasome inhibitor-resistant (PIR) IkappaBalpha degradation in B cells. Experimental Cell Research. 307: 15-25. PMID 15922723 DOI: 10.1016/J.Yexcr.2005.02.015 |
0.68 |
|
| 2002 |
Karimpour S, Lou J, Lin LL, Rene LM, Lagunas L, Ma X, Karra S, Bradbury CM, Markovina S, Goswami PC, Spitz DR, Hirota K, Kalvakolanu DV, Yodoi J, Gius D. Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation. Oncogene. 21: 6317-27. PMID 12214272 DOI: 10.1038/Sj.Onc.1205749 |
0.346 |
|
| Show low-probability matches. |